Physician

Chonyang Lu Albert, M.D.

According to 2025 Medicare claims, Chonyang Albert, M.D. (NPI: 1194084202) practices advanced heart failure and transplant cardiology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (NPI: 1407938525; TIN: 223371727) and primary practice location at 08901-1928. Albert is affiliated with the Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Albert's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 294 traditional Medicare patients, billed 716 HCPCS/CPT codes, and received $46,663 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 1,127 prescription claims across 276 beneficiaries totaling $422,363 in drug costs, led by Entresto (Sacubitril/Valsartan). DME data shows 29 claims. Open Payments data shows 27 records totaling $1,280. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $22,347 and ending at $46,663. Concurrently, Part D prescription costs have risen steadily, from $12,540 to $422,363. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	107	222	$22,347
2020	282	851	$82,957
2021	256	607	$63,368
2022	321	880	$85,705
2023	284	633	$57,812
2024	294	716	$46,663

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	35	194	$12,540
2016	37	188	$5,613
2017	30	133	$8,445
2018	15	32	$3,080
2019	73	214	$90,047
2020	206	1,430	$644,925
2021	231	1,847	$907,511
2022	322	2,534	$1,564,205
2023	347	3,248	$2,659,715
2024	276	1,127	$422,363

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	15	$34,131
2023	N/R	N/R	N/R
2024	N/R	29	$491

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	32	75	$176
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	25	26	$135
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	46	75	$105
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	43	131	$94
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	186	261	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Entresto	Sacubitril/Valsartan	132	6,968	$147,595
Jardiance	Empagliflozin	79	4,715	$86,163
Eliquis	Apixaban	36	2,280	$43,556
Farxiga	Dapagliflozin Propanediol	40	1,925	$32,393
Sirolimus	Sirolimus	16	900	$5,949

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$276
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	13	$215

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	27	$1,280	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chonyang Lu Albert, M.D.?

Tedicare shows public-source Medicare data for Chonyang Lu Albert, M.D. (NPI 1194084202), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chonyang Lu Albert, M.D. have ACO affiliation data?

Chonyang Lu Albert, M.D. is shown with ACO affiliation data for Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Chonyang Lu Albert, M.D.?

Chonyang Lu Albert, M.D. is linked to RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (billing NPI 1407938525) in the available physician profile data.

Does Chonyang Lu Albert, M.D. have Open Payments data?

Chonyang Lu Albert, M.D. has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.